Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Medtronic
Johnson and Johnson
Covington
Cantor Fitzgerald
Fuji
McKinsey
Cipla
US Department of Justice
Moodys

Generated: January 16, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,150,337

« Back to Dashboard

Summary for Patent: 6,150,337
Title: Specific modulation of Th1/Th2 cytokine expression by Ribavirin in activated T-lymphocytes
Abstract:Ribavirin is employed in a manner which is effective to modulate lymphokine expression in activated T cells. In particular, Ribavirin is used to suppress Type 2-mediated T cell responses and promote Type 1-mediated T cell response. Thus, instead of administering Ribavirin in its well-recognized role as an anti-viral agent, Ribavirin is herein used in the treatment of imbalances in lymphokine expression. Such imbalances may be found to be concomitants of allergic atopic disorders such as allergic asthma and atopic dermatitis, helminth infection and leishmaniasis, and various primary and secondary immunodeficiencies, which may or may not also be associated with viral infection.
Inventor(s): Tam; Robert (Costa Mesa, CA)
Assignee: ICN Pharmaceuticals, Inc. (Costa Mesa, CA)
Application Number:09/156,646
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 6,150,337

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Valeant Pharm Intl VIRAZOLE ribavirin FOR SOLUTION;INHALATION 018859-001 Dec 31, 1985 AN RX Yes Yes ➤ Subscribe ➤ Subscribe USE OF RIBAVIRIN TO INCREASE TYPE 1 CYTOKINE RESPONSE AND SUPPRESS TYPE 2 CYTOKINE RESP0NSE TO LYMPHOCYTES, INCLUDING METHODS THAT TAKE ADVANTAGE OF SUCH MODULATION TO TREAT INFECTIONS AND INFESTATIONS ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,150,337

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,479,463 Purine L-nucleosides, analogs and uses thereof ➤ Subscribe
5,767,097 Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes ➤ Subscribe
6,063,772 Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes ➤ Subscribe
6,509,320 Purine L-nucleosides, analogs and uses thereof ➤ Subscribe
6,455,690 L-8-oxo-7-propyl-7,8-dihydro-(9H)-guanosine ➤ Subscribe
6,423,695 Cytokine related treatments of disease ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,150,337

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 016597 ➤ Subscribe
Austria 216886 ➤ Subscribe
Austria 271063 ➤ Subscribe
Australia 1747897 ➤ Subscribe
Australia 4899997 ➤ Subscribe
Australia 6023898 ➤ Subscribe
Australia 700642 ➤ Subscribe
Australia 727177 ➤ Subscribe
Australia 736075 ➤ Subscribe
Brazil 9707154 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Julphar
Colorcon
Chubb
Novartis
Healthtrust
Harvard Business School
Queensland Health
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot